Silica-titania xerogel for solid phase spectrophotometric determination of salicylate and its derivatives in biological liquids and pharmaceuticals by unknown
Morosanova and Morosanova  Chemistry Central Journal  (2015) 9:64 
DOI 10.1186/s13065-015-0142-z
RESEARCH ARTICLE
Silica-titania xerogel for solid phase 
spectrophotometric determination of salicylate 
and its derivatives in biological liquids 
and pharmaceuticals
Maria A. Morosanova and Elena I. Morosanova*
Abstract 
Background: Salicylic acid and its derivatives are widely used drugs with potential toxicity. The main areas of salicy-
late derivatives determination are biological liquids and pharmaceuticals analysis.
Results: Silica-titania xerogel has been used for solid phase spectrophotometric determination of various salicylate 
derivatives (salicylate, salicylamide, methylsalicylate). The reaction conditions influence on the interaction of salicylate 
derivatives with silica-titania xerogels has been investigated; the characteristics of titanium(IV)-salicylate derivatives 
complexes in solid phase have been described. The simple solid phase spectrophotometric procedures are based on 
the formation of xerogel incorporated titanium(IV) colored complexes with salicylate derivatives. A linear response has 
been observed in the following concentration ranges 0.1–5, 0.5–10 and 0.05-4.7 mM for salicylate, salicylamide, and 
methylsalicylate, respectively. The proposed procedures have been applied to the analysis of human urine, synthetic 
serum, and pharmaceuticals.
Conclusions: The simple solid phase spectrophotometric procedures of salicylate derivatives determination based 
on the new sensor materials have been proposed for biological liquids and pharmaceuticals analysis.
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Background
Salicylic acid and its derivatives (acetylsalicylic acid, 
salicylamide, methylsalicylate) are widely used as anti-
inflammatory, analgesic drugs [1]. Acetylsalicylic acid 
is the most commonly used salicylate derivative, it is 
used as analgesic, antipyretic, and also as an antiplate-
let drug. Salicylamide is used as an analgesic and anti-
pyretic in several combination products. It is necessary 
to control their presence in biological fluids due to the 
potential toxicity. Methylsalicylate is also used as an anti-
inflammatory drug, but it is highly toxic if ingested and 
is only prescribed for external application. The drugs of 
this group have common pharmacological effect and all 
of them are toxic in high concentrations. A plasma level 
higher than 2.2 mM of salicylate is considered to be toxic 
[2], and the level higher than 4.3 mM is regarded as lethal 
[1]. The therapeutic range (0.5–1.5  mM of salicylate in 
plasma) is very close to the toxicity level.
Monitoring salicylates concentration in biological liq-
uids is important for controlling the dose and frequency 
of salicylate derivative drug administration as all the 
salicylate derivatives mostly convert to salicylate in the 
organism. Accidental overdoses of salicylates are consid-
ered to be common in children. Salicylates are one of the 
toxicants that must be determined in serum and urine 
of patients of emergency department [3]. The allergenic 
capacity of salicylates also dictates the necessity of moni-
toring their levels in biological liquids. Another essential 
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field for salicylate derivatives analysis is the pharmaceuti-
cals quality control.
Various methods have been proposed for the determina-
tion of salicylic acid and its derivatives in biological liquids 
and pharmaceutical preparations: chromatography [4, 5], 
spectroscopic [6–9], electrochemical [10–15]. Many spec-
trophotometric and electrochemical methods of salicylate 
determination are based on its ability of forming com-
plexes with metals: colored complex of salicylate with iron 
(III) is used in the classical method of salicylate determi-
nation (Trinder test) in biological samples [6]; complexing 
reaction with transition metal ions is employed in ion-
selective electrodes construction [12–14].
The development of the simple methods of salicylate 
determination is a high-demand task, considering the 
wide use of salicylate derivatives in medical practice. The 
search for new sensor materials with an ability to form 
complexes with salicylates is a highly perspective goal.
Titanium(IV) forms colored complexes in weakly acidic 
solutions with some aliphatic and aromatic ligands. For 
example, salicylic acid and 5-chlorosalicylic acid are 
widely used for spectrophotometric determination of 
titanium(IV) [16].
In our previous works the ability of titanium(IV) 
embedded in silica-titania xerogel matrix to form com-
plexes with ascorbic acid, polyphenols, dopamine, hydro-
gen peroxide, and fluoride ions was exploited to develop 
the solid phase spectrophotometric procedures for these 
substances determination [17–20].
The aim of the present work was to study the complex 
forming between the silica-titania xerogel and salicylate, 
salicylamide, or methylsalicylate and to choose the condi-
tions of these salicylate derivatives and also acetylsalicylic 
acid determination in pharmaceuticals and salicylate 
determination in biological liquids.
Results and discussions
Interaction of silica‑titania xerogel with salicylate 
derivatives
The complexes of salicylate and titanium(IV) in solid 
phase are discussed in literature. The interaction of tita-
nium dioxide surfaces with various complexing agents, 
including salicylate, is described. The important inter-
action which is involved in the titanium(IV) butoxyde–
salicylate complex formation in mixed crystals is the 
hydrogen bonds formation [21]. It is different from the 
titanium(IV) butoxyde–catechol complexes, which are 
shown to rely mostly on van der Waals interactions. In 
[22] the hydrogen bonds are also shown to be important 
for salicylate-titanium complexes formation on the sur-
face of solid titanium dioxide, as they are necessary for 
surface titanium(IV) to retain their normal coordination. 
However, the hydrogen bond is only formed if salicylate 
interacts with one titanium ion, and not when salicylate 
interacts with two titanium ions (the schemes of these 
two complexes are presented in Fig.  1). The complexes 
of titanium(IV) with salicylamide and methylsalicylate 
in solid phase have not been studied. As the described 
above materials have surfaces similar to those of our sil-
ica-titania xerogels the complexes may also be similar.
In the present work the silica-titania xerogel used for 
complex formation study was prepared using the sol–gel 
technology. Tetraethoxysilane and titanium(IV) tetraeth-
oxyde were used as precursors. The xerogel with 12.5 % 
titanium(IV) tetraethoxyde content was chosen consid-
ering the micropore distribution analysis [20]. Then the 
optimal conditions for the complex forming reaction 
were investigated.
The interaction of the silica-titania xerogel with salicy-
late, salicylamide, and methylsalicylate was studied in the 
present work. After the contact of the silica-titania xero-
gel with salicylate derivatives the xerogel’s color changed 
from white to pale yellow which signified the complex 
formation. The xerogels spectra after complex forming 
reaction with salicylate derivatives showed broad absorp-
tion bands at 390–420  nm the maxima being 410  nm 
(Fig. 2). When compared to the spectra of studied salicy-
late derivatives the xerogel spectra displayed significant 
bathochromic shift (70 nm for salicylate, 90 nm for salic-
ylamide, 95  nm for methylsalicylate). In the following 
experiments colored xerogels absorbance was measured 
at 410 nm.
The reaction conditions (pH of the solution and reac-
tion time) influence on the complexing reaction was 
studied. The pH influence was studied in the range of 
1.0-11.0 and the optimum was found out to vary for 
the different salicylate derivatives (Fig.  3). The maxi-
mal values of the xerogels absorbance were observed 
at pH 1.5–2.5 for salicylate and salicylamide and at pH 
7.0–8.0 for methylsalicylate. In the case of salicylate and 
salicylamide the pH increase leads to the decrease of the 
formed complexes amount which results in the decrease 
of the absorbance value. These data correspond with the 
a b
Fig. 1 Two possible complexes of salicylate with titanium(IV) on the 
titanium dioxide surfaces [22]. a The complex of salicylate with two 
titanium(IV) ions, b the complex of salicylate with one titanium(IV) 
ion
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literature: the acidic media (pH < 2.5) has been reported 
to be optimal for the salicylate-titanium complexes for-
mation on the surface of solid titanium dioxide [22]. The 
degradation of methylsalicylate in the acidic media was 
described in [4], as it was observed by liquid chromato-
graphic method; such degradation could contribute to 
the pH optimum shifting for methylsalicylate. In the fol-
lowing experiments the following conditions were used 
for the reactions: pH 2.0 for salicylate and salicylamide 
and pH 7.6 for methylsalicylate.
The effect of contact time with salicylate derivatives 
on the silica-titania xerogel absorbance was studied. The 
equilibrium in these complexing reactions was shown 
to be reached in 15  min (Fig.  4). An earlier developed 
approach [23] allowed characterizing the heterogeneous 
reaction of salicylate derivatives complex forming. Half-
reaction periods (T1/2) that characterize the reaction 
kinetics were calculated (4.5, 4.0, and 5.8 min for salicy-
late, salicylamide, and methylsalicylate, respectively).
The study of the surface complex formation process is 
an important step in the description of new solid mate-
rials properties [18, 19, 22, 24, 25]. The complex stoichi-
ometry and the equilibrium constants were determined 
using the equilibrium shift method developed earlier by 
authors [18]. Solid phase spectrophotometric determina-
tion of salicylate derivatives using silica-titania xerogel 
was described by the following equation:
The equilibrium constant of the reaction (1) can be 
described as following: 
([≡ Ti− Ln]/[≡ Ti− (OH)n]) can be defined as L, the 
rate of complexation of the titanium in the xerogel matrix 
([≡ Ti− Ln] and [≡ Ti− (OH)n] are the concentrations 
of complexed and non-complexed titanium(IV) in the 
solid phase). L was calculated as Ai/(Aex − Ai), where 
Ai is the xerogel’s absorbance after reaction and Aex is 
the xerogel’s absorbance after reaction with the excess 
of corresponding salicylate derivative. Using the pro-
cedure described in [18] the lgL can be expressed as a 
linear function of lg[HL] [see Eq.  (3)], which allows the 
(1)≡ Ti− (OH)n + nHL =≡ Ti− Ln + nH2O.
(2)Keq= [ ≡ Ti− Ln]/[≡ Ti− (OH)n][HL]
n,
(3)
lg([ ≡ Ti− Ln]/[≡ Ti− (OH)n]) = lgKeq + nlg[HL].
a
b
Fig. 2 Absorption spectra of xerogels after reaction with salicylate 
derivatives (time of contact with salicylate derivatives is 15 min). a 
Chemical structures of salicylate derivatives and b absorption spectra 
of xerogels after reaction with salicylate derivatives 1 mM solutions. 1 















Fig. 3 The dependence of silica-titania xerogels absorbance on pH 
after the contact with salicylate derivatives. λ 410 nm, time of contact 
with salicylate derivatives is 15 min. 1 2 × 10−3 M sodium salicylate, 2 














Fig. 4 The dependence of silica-titania xerogels absorbance on the 
time of contact with salicylate derivatives. λ 410 nm. 1 2 × 10−3 M 
sodium salicylate, pH 2.0, 2 3∙× 10−3 M salicylamide, pH 2.0, 3 2.5∙× 
10−3 M methylsalicylate, pH 7.6
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determination of the complex stoichiometry, n, and the 
equilibrium constant, Keq. The equilibrium concentra-
tions of salicylate derivatives in the liquid phase ([HL]) 
were determined using the preliminary constructed cali-
bration curves and the absorbance of the salicylate deriv-
atives solutions after the contact with the silica-titania 
xerogel powders. The data were approximated by linear 
dependences in the coordinates lgL on lg[HL] using the 
least squares method. The slopes of the resultant depend-
ences allowed determining the stoichiometry of the pro-
duced complexes while the intercept with the ordinate 
axis provided the equilibrium constants of the hetero-
geneous reactions. These characteristics of the salicylate 
derivatives complexes with titanium(IV) are given in 
Table  1. Salicylic acid can form complexes with one or 
two titanium ions as described in [22, 25], and the com-
plexes with two metal ions are less stable, which corre-
sponds with our data (salicylate complexes are less stable 
than the other complexes).
Selected conditions were applied to solid phase spec-
trophotometric determination of salicylate derivatives.
Analytical application
In order to develop analytical procedures of salicylate 
derivatives determination we investigated the depend-
ency between the silica-titania xerogels absorbance and 
the analyte concentration. The calibration curves were 
constructed using standard sample solutions at ten con-
centrations with least squares linear regression method. 
Analytical ranges and limits of detection (LOD) are given 
in Table 2. The intercept values did not differ significantly 
(n = 3, p > 0.05) from the blank (absorbance of uncolored 
xerogel).
Salicylate determination in biological liquids
The developed solid phase spectrophotometric proce-
dures were applied to biological liquids analysis (Table 3). 
The recoveries show that the components of synthetic 
serum and human urine did not interfere the salicylate 
determination significantly, which allowed the use of the 
silica-titania xerogel for biological liquids analysis.
The analytical range of the developed procedure made 
it possible to determine various salicylate levels in the 
serum samples: below the therapeutic dose (<0.5  mM), 
the therapeutic dose (0.5–1.5  mM), and overdose 
(2.0 mM).
The analysis of the real sample of human urine proved 
that the developed procedure allowed the determination 
of salicylate processed by the organism which is often 
required in the medical applications.
The concentrations found in biological liquids sam-
ples have shown good agreement with the results of 
Trinder salicylate test (Table  4). The suitability of the 
proposed procedures for biological liquids analysis has 
been proven. The proposed procedures can be applied 
for low-cost, fast salicylate analysis. Compared to classi-
cal Trinder test the solid phase spectrophotometric pro-
cedures can be characterized by faster determination, 
lower content of harmful acidic compounds, and better 
stability.
Determination of salicylate derivatives in pharmaceuticals
The determination of salicylate derivatives in pharmaceu-
tical samples always comprises the difficulties of various 
interferences, as many drugs have complex composition 
and may contain other active substances in comparable 
quantities.
Table 1 Characteristics of  titanium(IV)—salicylate deriva-
tives complexes in solid phase





Table 2 Analytical characteristics of  solid phase spectro-
photometric determination of  salicylate derivatives (λ 









Sodium salicylate 0.1–5 A = 150·C 0.9968 0.02
Salicylamide 0.5–10 A = 86·C 0.9983 0.03
Methylsalicylate 0.05–4.7 A = 125·C 0.9976 0.01
Table 3 Recovery test of  solid phase spectrophotomet-
ric determination of salicylate in biological liquids (n = 3, 
P = 0.95)
a Synthetic serum composition is taken from [12]
b Collected 1 h after oral administration of 1000 mg of acetylsalicylic acid
Sample Added (mM) Found (mM) RSD  (%) Recovery  (%)
Synthetic 
seruma
0.5 0.49 ± 0.10 10.9 98.0
1.0 0.97 ± 0.15 8.4 97.0
1.5 1.42 ± 0.05 1.9 94.6
2.0 2.09 ± 0.04 1.0 104.5
Urineb 0 0.46 ± 0.07 8.3
0.25 0.70 ± 0.09 7.2 96.0
0.625 1.08 ± 0.07 3.5 99.2
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The difference in the pH optima for complex formation 
was used for salicylate/methylsalicylate determination in 
their mixtures (Table 5), which can also be important for 
mixed formulations.
The procedures for solid phase spectrophotometric 
determination of salicylate derivatives were applied to 
various pharmaceuticals analysis with the use of standard 
addition method. Acetylsalicylic acid was hydrolyzed to 
salicylate in the presence of sodium hydroxide prior to 
analysis. Reproducibility of real samples analysis is pre-
sented in Table 6. Relative standard deviation of 2–13 % 
and recovery of 90–100 % were achieved.
The salicylate derivatives concentrations found in the 
pharmaceuticals have shown good agreement with the 
content declared by the manufacturer (Table 4). Among 
other advantages the determination in the presence of 
other active substances should be noted. The analgesic, 
anti-inflammatory pharmaceuticals based on salicylate 
derivatives often contain other active substances, such 
as paracetamol, caffeine, or menthol, and the absence 
of their interference broadens the range of possible 
applications.
The proposed procedures can be characterized as 
simple and fast and do not require complex labware or 
special storage conditions, and the analytical range is 
suitable for pharmaceuticals analysis. The silica-titania 
xerogel used as the sensor material is highly stable com-
pared to other sensor materials.
Experimental
Reagents
The following reagents were purchased from Acros 
Organics: hydrochloric acid, sodium tetraborate, sodium 
salicylate, methylsalicylate, salicylamide, sodium hydro-
carbonate, citric acid, sodium chloride, aminoacids, 
titanium(IV) tetraethoxyde, and tetraethyl orthosilicate. 
All the reagents were of analytical grade, titanium(IV) 
tetraethoxyde was of technical grade.
Stock solutions of salicylate and salicylamide were 
prepared with doubly distilled water. Stock solution of 
methylsalicylate was prepared with ethanol. Only freshly 
prepared solutions of these substances were used.
Trinder reagent was prepared as in [13]: 4.0  g of iron 
(III) nitrate nonahydrate and 5.0 g of trichloroacetic acid 
were dissolved in 100.0 mL of doubly distilled water.
Instrumentations
Silica-titania xerogel was obtained by drying in Ethos 
microwave complex (Milestone, Italy).
Light absorbance of the xerogels water suspensions 
was measured using KFK-3 spectrophotometer (ZOMZ, 
Russia) and glass cuvettes (0.1  cm). Cuvette filled with 
non-colored xerogel water suspension was used as 
blank.
Light absorbance of the salicylate derivatives solutions 
was measured using KFK-3 spectrophotometer (ZOMZ, 
Russia) and quartz cuvettes (1.0 cm).
The pH value was measured using Expert-001 (Eco-
nix Expert, Russia) potentiometer with pH-sensitive 
electrode.
Table 4 Solid phase spectrophotometric determination of salicylate derivatives in real samples using the standard addi-
tion method (n = 3, P = 0.95)
DC content declared by manufacturer
TT Trinder salicylate test
a Contains additional active substances: menthol 59.1 mg/g, eucalyptus oil 19.7 mg/g, turpentine oil 14.7 mg/g
b Contains additional active substances: paracetamol 180 mg/tablet, caffeine 30 mg/tablet
c Synthetic serum composition is taken from [12]
d Collected 1 h after oral administration of 1000 mg of acetylsalicylic acid
Sample Analyte Found (independent method) Found (proposed method)
Deep Heat creama Methylsalicylate 128 mg/g (DC) 123 ± 8 mg/g
Citramon tabletsb Acetylsalicylic acid 240 mg/tablet (DC) 220 ± 10 mg/tablet
Acetylsalicylic acid tablets Tatkhim Acetylsalicylic acid 500 mg/tablet (DC) 500 ± 20 mg/tablet
Acetylsalicylic acid tablets Medisorb Acetylsalicylic acid 500 mg/tablet (DC) 510 ± 20 mg/tablet
Synthetic serumc, containing 1 mM salicylate Salicylate 1.03 ± 0.05 mM (TT) 0.97 ± 0.15 mM
Urine sampled Salicylate 0.42 ± 0.01 mM (TT) 0.46 ± 0.07 mM
Table 5 Determination of  salicylate and  methylsalicylate 
in mixed solutions (n = 3, P = 0.95)
Composition pH Found, mM
Salicylate 2.5 mM
Methylsalicylate 3.75 mM
2.0 Salicylate 2.5 ± 0.2
Methylsalicylate 1.9 mM
Salicylate 5.0 mM
7.6 Methylsalicylate 1.97 ± 0.5
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Surface area and porosity BET analysis was carried by 
using ASAP 2000 (Micromeritics, Norcross, GA, USA).
Synthesis of silica‑titania xerogel
Silica–titania xerogel was obtained using earlier devel-
oped procedures [18]: 20.0  mL of 0.05  M hydrochloric 
acid in 50 % ethanol solution was added to 10.0 mL of the 
precursors mixture (12.5  % titanium(IV) tetraethoxyde, 
87.5 % tetraethoxysilane) while stirring. The wet gel was 
formed in the next 72 h. The wet gels were dried at 800 W 
microwave irradiation for 10 min to get dry xerogels.
The main characteristics of the xerogel: BET surface 
area is 540 m2/g, micropore volume is 0.14 cm3/g.
Interaction of silica‑titania xerogel with salicylate 
derivatives at different pH
0.10  g of silica-titania xerogel was added to 5.0  mL of 
solution, containing 2  mM salicylate, 3  mM salicyla-
mide, or 2.5 mM methylsalicylate. pH of the solution was 
adjusted adding 0.01–2.0  mL of 0.5  M sulfuric acid, or 
1.0 mL of phosphate buffer (pH 4–8), or 1.0 mL of borate 
buffer (pH 8–12). The obtained mixture was shaken for 
15 min. Then the xerogels light absorbance was measured 
at 410 nm and pH of the solution was measured.
Interaction of xerogel with salicylate derivatives kinetics 
studies
0.10  g of silica-titania xerogel was added to 5.0  mL of 
solution, containing 2 mM salicylate (pH 2), 3 mM salicy-
lamide (pH 2), or 2.5 mM methylsalicylate (pH 7.6).The 
obtained mixture was shaken for 2–20  min. Then the 
xerogels light absorbance was measured at 410 nm.
Determination of complexes composition and equilibrium 
constants
0.10  g of silica-titania xerogel was added to 5.0  mL of 
solution, containing 0.1–25 mM salicylate (pH 2), 0.5–
10 mM salicylamide (pH 2), or 0.05–4.7 mM methylsal-
icylate (pH 7.6). The obtained mixture was shaken for 
15  min. Then the xerogels light absorbance was meas-
ured at 410  nm. The solution absorbance was meas-
ured at 340 nm for salicylate, 320 nm for salicylamide, 
315 nm for methylsalicylate. The concentration of unre-
acted salicylate derivative left in solution was deter-
mined using calibration curve at the corresponding 
wavelength.
Calibration curves
0.10  g of silica-titania xerogel was added to 5.0  mL of 
solution, containing 0.1–5  mM salicylate (pH 2), 0.5–
10  mM salicylamide (pH 2), or 0.05–4.7  mM methyl-
salicylate (pH 7.6). The obtained mixture was shaken for 
15 min. Then the xerogels light absorbance was measured 
at 410  nm. Calibration curves were obtained using the 
least squares method.
Determination of salicylate derivatives in synthetic serum
Synthetic serum was prepared as in [12]. 1.0  mL of 
Trinder reagent was added to 5.0 mL of synthetic serum 
containing 0.1–2 mM salicylate. After 30 min the colored 
solution absorbance was measured at 620 nm (l 1.0 cm).
0.10 g of silica-titania xerogel and 0.1 mL of 0.5 M sulfu-
ric acid were added to 5.0 mL synthetic serum containing 
0.1–2 mM salicylate, the mixture was shaken for 15 min. 
After that the xerogel light absorbance was measured.
Table 6 Recovery test of solid phase spectrophotometric determination of salicylate derivatives (n = 3, P = 0.95)
a Contains additional active substances: menthol 59.1 mg/g, eucalyptus oil 19.7 mg/g, turpentine oil 14.7 mg/g
b Contains additional active substances: paracetamol 180 mg/tablet, caffeine 30 mg/tablet
Analyte Sample Added (mM) Found (mM) RSD  (%) Recovery  (%)
Methylsalicylate Deep heat creama 0 1.01 ± 0.24 13.6
0.91 1.85 ± 0.27 8.2 92.3
1.82 2.83 ± 0.24 4.9 100.0
Acetylsalicylic acid Acetylsalicylic acid tablets Medisorb 0 0.57 ± 0.06 6.4
0.55 1.07 ± 0.06 3.4 90.9
1.1 1.68 ± 0.06 2.2 100.9
Acetylsalicylic acid tablets Tatkhim 0 0.69 ± 0.09 7.6
0.55 1.20 ± 0.09 4.5 92.7
1.1 1.79 ± 0.09 2.9 100.0
Citramon tabletsb 0 0.49 ± 0.09 10.6
0.55 1.02 ± 0.15 7.7 96.4
1.1 1.58 ± 0.15 5.8 99.1
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Determination of salicylate derivatives in human urine 
sample
The research was carried out according to the World 
Medical Association Declaration of Helsinki, and 
informed consent was obtained from the subject. The 
research was also approved by MSU Bioethics Commit-
tee [decision N 23-ch(3)]. Author of this work volun-
teered for the research: the healthy volunteer received a 
1000 mg acetylsalicylic acid dose by oral administration. 
After 1 h the urine sample was collected.
1.0  mL of 0–3.1  mM salicylate was added to 1.0  mL 
of urine, and then 2.0 mL of Trinder reagent was added. 
After 30 min the colored solution absorbance was meas-
ured at 620 nm (l 1.0 cm).
2.5 mL of 0–1.3 mM salicylate was added to 2.5 mL of 
urine, and then 0.10 g of silica-titania xerogel and 0.1 mL 
of 0.5  M sulfuric acid were added. The mixture was 
shaken for 15 min and the xerogel light absorbance was 
measured.
Determination of methylsalicylate in pharmaceutical 
samples
1.50 g of Deep Heat cream was diluted in ~20 mL of etha-
nol, and then boiled for 5 min. After cooling the solution 
was filtered to a 25.0 mL volumetric flask. Then the flask 
was diluted to the mark with ethanol. 0.1 mL of diluted 
sample was mixed with 3.75 mL of doubly distilled water, 
1.0  mL of borate buffer (pH 8.5), 0.15  mL of standard 
methylsalicylate solution, and 0.10 g of xerogel, and then 
shaken for 15 min. After that the xerogel light absorbance 
was measured. Methylsalicylate concentration was deter-
mined using standard addition method.
Determination of acetylsalicylic acid in pharmaceutical 
samples
Tablets, containing acetylsalicylic acid, were ground to 
powder, and an amount of powder, containing ~0.05  g 
of acetylsalicylic acid was weighed. 5.0 mL of 2 M NaOH 
was added to the powder, and then diluted with ~20 mL 
of doubly distilled water. The solution was heated for 
5  min. After the cooling the solution was filtered to a 
50.0  mL volumetric flask. Then the flask was diluted to 
the mark with doubly distilled water. This acetylsalicylic 
acid hydrolysis procedure completeness was verified by 
applying it to standard solutions of acetylsalicylic acid. 
10.0 mL of hydrolyzed sample was mixed with 20.0 mL of 
standard salicylate solution, then pH was adjusted to 6.2, 
and then the solution was transferred to a 50.0 mL volu-
metric flask, which was diluted to the mark with doubly 
distilled water. 2.5 mL of diluted sample was mixed with 
2.5 mL of doubly distilled water, 0.1 mL of 0.5 M sulfuric 
acid, and 0.10 g of silica-titania xerogel, and then shaken 
for 15 min. After that the xerogels light absorbance was 
measured. Acetylsalicylic acid concentration was deter-
mined using standard addition method.
Conclusion
The reliable and simple method of salicylate deriva-
tives determination based on the xerogel incorporated 
titanium(IV) complexes with salicylate derivatives has 
been proposed. In comparison with other methods 
of salicylate derivatives determination the proposed 
method key characteristics is its simplicity, whereas the 
analytical ranges are comparable with other methods [5, 
6, 10, 11]. The procedures for solid phase spectropho-
tometric determination of salicylate derivatives in bio-
logical liquids and pharmaceuticals have been proposed. 
These new sensor materials are stable and ready to use 
and can be successfully applied to biological liquids and 
pharmaceuticals analysis.
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